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BACKGROUND: Elderly patients constitute the majority of patients with acute coronary 
syndrome. Nevertheless, due to a paucity of data, decision-making on the use of percutaneous 
coronary intervention in this patient group is mainly empirical. Old age is associated with 
higher risk of adverse outcome of PCI. It is however not well-known what other factors than 
age that are of prognostic significance. Likely, considering the heterogeneity of the patient 
group, there is a subgroup of elderly patients for which the prospects of gaining from 
intervention are greater than for others. By studying and evaluating factors that may be of 
prognostic significance this subgroup of elderly patients may be identified and so a more 
optimal use of PCI could be attained.   
 
OBJECTIVE: To evaluate the prognosis of elderly patients undergoing PCI in the setting of 
ACS. More specifically, to retrospectively identify predictors of all-cause long-term mortality 
among patients ≥ 80 years, i.e. the “oldest” old. 
 
METHODS: Data on 64 patients ≥80 years undergoing PCI with the indication ACS at the 
Sahlgrenska University Hospital in Gothenburg, Sweden, were retrospectively collected in a 
database. In order to identify predictors of long-term mortality multivariate regression 
analysis was performed. Kaplan-Meier curves were constructed to illustrate the relation 
between factors of prognostic significance and survival over time. 
 
RESULTS: 4-year all-cause mortality in the current study population was about 40%. Age, 
heart rate, glomerular filtration rate and prior CABG were identified as independent predictors 
of long-term mortality. 
 
CONCLUSIONS: In an elderly patient population patients with an age of >85 years, increased 
heart rate, renal insufficiency and prior CABG are at higher risk of adverse long-term 
outcome of PCI and so potentially have less to gain from intervention. However, further 
studies, in particular prospective ones, are needed to validate these results.  
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ABBREVIATIONS 
 
ACS    acute coronary syndrome 
BMI  body mass index 
CABG  coronary artery bypass grafting 
CAD   coronary artery disease 
CVD  cardiovascular disease 
ECG  electrocardiogram 
GFR  glomerular filtration rate 
LVEF  left-ventricular ejection fraction  
MACE  major adverse cardiac events 
MI  myocardial infarction 
NSTE-ACS   non-ST-elevation acute coronary syndromes 
NSTEMI  non-ST-elevation myocardial infarction 
PCI  percutaneous coronary intervention 
RCT randomised clinical trial 
STEMI  ST-elevation myocardial infarction 
UAP  unstable angina pectoris 
WHO  World Health Organization 
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INTRODUCTION 
BACKGROUND 
Cardiovascular diseases (CVDs), defined as diseases of the heart, vascular diseases of the 
brain and diseases of blood vessels, are the leading cause of death and disability globally (1). 
Even though CVDs to a large extent are preventable mortality and morbidity keep rising from 
a global perspective. According to the World Health Organization (WHO) this is a result of an 
increase in the prevalence of cardiovascular risk factors caused by the aging of populations 
and the globalisation of unhealthy behaviours. 
   The major categories of CVDs are cerebrovascular disease and coronary artery disease 
(CAD) (1). Out of these, the latter category causes most death and disability, both among men 
and women. The main underlying pathogenesis of CAD, as well of cerebrovascular disease, is 
the process of atherosclerosis (1, 2). This refers to a chronic inflammation of the arterial wall 
which leads to the formation of atheromatous plaques with subsequent obstruction of the 
arterial lumen and reduction of blood flow. The development of atherosclerotic plaques is a 
slow process influenced by a number of risk factors such as smoking, high blood pressure and 
high cholesterol levels (3). 
   Atherosclerosis is considered as a chronic disease with stable and unstable periods 
depending on variations in inflammatory activity (4, 5). In the heart, reduced coronary blood 
flow with subsequent myocardial ischemia typically manifests itself clinically as diffuse pain 
or discomfort in the chest and changes in the ECG. However, atypical manifestations are not 
uncommon and myocardial ischemia may also exist in the absence of clinical symptoms and 
signs (2). In stable CAD the characteristic clinical manifestation, known as stable angina 
pectoris, is a radiating chest pain elicited by physical exercise and relieved by rest or the 
administration of nitroglycerin (2, 6). The pathophysiology of stable CAD is an inability of 
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stenosed coronary arteries to increase blood flow, and thereby the delivery of oxygen, 
sufficiently to meet an increase in myocardial demand for oxygen, e.g. during physical 
exercise. During unstable periods CAD may manifest itself clinically as acute coronary 
syndrome (ACS). ACS is a generic term comprising the conditions of unstable angina pectoris 
(UAP), myocardial infarction (MI) and sudden coronary death (5, 6). These conditions are, in 
contrast to stable CAD, usually caused by an abrupt reduction in coronary blood flow due to 
plaque disruption with subsequent thrombus formation and potential artery occlusion. The 
extension of myocardial injury in ACS is determined by the degree of ischemia which in turn 
is determined by several factors (4-6). Belonging to these factors are the duration and totality 
of artery occlusion and the extent to which there is collateral blood flow to the myocardium 
distal to the occlusion. In contrast to UAP, in which vessel occlusion of short duration causes 
transient myocardial ischemic injury, ischemia in MI persists long enough to cause 
myocardial cell death or necrosis. Myocardial necrosis develops 15-30 minutes after the onset 
of ischemia and is detected via the release of specific proteins, e.g. cardiac troponin, into the 
blood by damaged myocytes. Based on changes in the ECG MI is clinically classified as 
either non-ST-elevation myocardial infarction (NSTEMI) or ST-elevation myocardial 
infarction (STEMI) (7, 8). In NSTEMI necrosis is limited to the inner, or subendocardial, part 
of the myocardial wall. In STEMI, due to more severe ischemia usually caused by occlusion 
of a major coronary artery, necrosis comprises the entire myocardial wall.    
 
The treatment of coronary artery disease aims at relieving symptoms as well as preventing the 
progression of atherosclerosis, thereby reducing the risk of the development of acute coronary 
syndrome (2, 5). In ACS the principal objective of treatment, apart from symptom relief, is 
the upheaval of myocardial ischemia by the restoration of coronary blood flow (5). Treatment 
also aims at reducing the risk of heart failure and arrhythmia secondary to myocardial 
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ischemic damage. Furthermore, an important objective of treatment in ACS is the prevention 
of recurrent thromboembolic events. 
    The principal treatment modalities for CAD are lifestyle changes, pharmacological 
treatment and myocardial revascularisation (2, 5, 9). Myocardial revascularisation refers to 
invasive strategies to restore blood flow in stenosed or occluded coronary arteries and 
comprises coronary artery bypass grafting (CABG) and percutaneous coronary intervention 
(PCI) (10). In contrast to CABG, PCI aims at restoring the blood flow of the native coronary 
artery or arteries by balloon dilatation and stent implantation in stenosed or occluded sections.     
   According to established guidelines revascularisation therapy is indicated in all patients 
presenting with symptoms of myocardial ischemia of duration shorter than 12 hours, and in 
some patients with symptoms of longer duration, and signs of STEMI in the ECG (8). In this 
context PCI, if performed within 1.5-2 hours from the first medical contact, is the preferred 
strategy of reperfusion (8, 9). The benefits of so called primary PCI, which is defined as PCI 
without prior or simultaneous fibrinolysis, compared to pharmacological reperfusion include a 
decrease in the risk of reinfarction, stroke and death (provided it is performed within the time 
limit mentioned above) (5). In UAP and NSTEMI, together referred to as non-ST-elevation 
acute coronary syndromes (NSTE-ACS), an invasive strategy of reperfusion is recommended 
in patients at high risk for cardiovascular events and death and in patients presenting with 
either recurrent symptoms or stress-inducible ischemia (5, 7, 10). Indicators of high risk e.g. 
include relevant changes in troponin-levels, dynamic ST- or T-wave-changes in the ECG, 
diabetes mellitus, renal insufficiency and old age. The choice of invasive reperfusion strategy, 
PCI or CABG, in NSTE-ACS is based on the clinical status of the patient in combination with 
the severity and distribution of CAD. PCI is suitable in most cases of single-vessel disease 
whereas in multi-vessel disease the choice between PCI and CABG is more complex.  
 
 4 
 
The guidelines on the use of reperfusion therapy in ACS described above are based on data 
derived from randomised clinical trials (RCTs) or meta-analyses (7, 8, 10). PCI has been the 
subject of more RCTs than any other intervention. However, data regarding PCI in certain 
patient subgroups such as the elderly is still limited (9). One reason for this is that elderly 
patients are often excluded from trials because of their generally high rates of co-morbidities 
(11). Furthermore, old age in itself is frequently used as an exclusion criterion in RCTs (12, 
13).  
   Despite that evidence on the use of PCI in elderly patients remains limited there are data 
available indicating that PCI is beneficial in elderly patients with ACS. A recently published 
review of RCTs and retrospective studies, in which persons ≥ 65 years were defined as 
elderly, concluded that primary PCI compared to fibrinolysis significantly reduced short-term 
morbidity (recurrent MI and stroke) and mortality in elderly patients presenting with STEMI 
(13). Furthermore, another analysis of 22 RCTs showed that the size of the reduction in short-
term (30 days) morbidity and mortality with PCI compared to fibrinolysis in STEMI is 
independent of the patient’s age (14). In NSTE-ACS the advantages of PCI over conservative 
medical therapy have been less clear than in STEMI as shown by either an increased risk with 
PCI or no difference between the two treatment options (13). However, more recent studies, 
conducted after stent implantation became routine in PCI, have demonstrated significant 
reductions in short-term mortality and morbidity among elderly patients who receive invasive 
treatment.  
   Concerning outcomes of PCI in elderly patients compared to younger patients observational 
studies have demonstrated that old age is associated with both higher in-hospital mortality 
rates and frequent PCI-related complications such as renal failure and bleedings (13, 15-17). 
Results from studies on mid- and long-term outcomes of PCI are more ambiguous. For 
example, incidence rates among elderly patients of major adverse cardiac events (MACE), 
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defined as the combined events of deaths, revascularization and myocardial infarction, have 
been found to be both higher and similar to rates among younger patients (18-21). Moreover, 
higher mortality rates were observed among elderly patients at 12 and 36 months follow-up.  
 
The paucity and inconsistency of data on the use of PCI in the elderly has several 
implications. The underrepresentation of elderly patients in RCTs restricts the applicability of 
prevailing guidelines in clinical practice (7, 12). In the present situation, it is difficult for 
physicians to make well-founded decisions on the use of PCI in the elderly. Elderly patients 
have been found to be less likely than younger patients to undergo PCI, partly because some 
of the existing data suggest that age is associated with negative outcomes (22-24).  
   The finding that elderly patients undergo PCI to a lesser extent than younger patients holds 
even after adjusting for contraindications and co-morbidities that may be of relevance (22-24). 
The suggestion that elderly patients are sometimes withheld PCI solely because of their age is 
contrary to prevailing ethical principles (9). Even if age itself has in some studies been found 
to be a predictor of death and other adverse outcomes of PCI (13, 15, 20, 25) the elderly 
constitute a heterogeneous group. The term ‘elderly’ is a broad term comprising the “young” 
old (65-74 years), the “older” old (75-84 years) and the “oldest” old (≥85 years) (26). 
Moreover, the elderly have considerable individual variation in co-morbidities and physical 
capabilities (15). In view of the heterogeneity of the elderly patient group it is likely that some 
elderly patients have better prospects of gaining from PCI in the setting of ACS than others. 
However, identifying this subgroup of elderly patients for which the advantages of PCI 
exceed the risks requires data on which factors other than age that are of prognostic 
significance. Studies aiming at identifying predictors of negative outcome of PCI among 
elderly patients have been conducted (13, 15, 16, 18, 20, 21, 25, 27-31). However, those 
studies are mainly retrospective observational cohort studies with a follow-up period of one 
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year or less. Further studies, in particular prospective ones, are needed to allow for physicians 
to make well-founded decisions and so optimizing the use of PCI in elderly patients with 
ACS.  
 
OBJECTIVE OF STUDY 
Provided that the subgroup of elderly patients for whom the benefits of undergoing PCI 
exceed the risk can be identified a more optimal use of the procedure in this patient 
population may be attained. Identification of patients who have the potential of benefiting 
from intervention can be made possible by studying and evaluating factors that may be of 
prognostic significance. The objective of this master thesis is to evaluate the prognosis of 
elderly patients undergoing PCI in the setting of ACS. More specifically, the objective is to 
retrospectively evaluate predictors of long-term mortality among patients ≥ 80 years, i.e. the 
“oldest” old. The thesis constitutes part of a larger research project aiming at, by both 
retrospective and prospective studies, elaborating a predictive model that can be used in 
clinical practice for identifying elderly patients who, in terms of risks related to benefits, are 
suitable candidates for PCI. 
SIGNIFICANCE OF THE STUDY 
Despite the fact that the elderly constitute the majority of patients with ACS prevailing 
guidelines, by being based on studies mainly including younger patients, are of limited use in 
decision-making on PCI in this patient group. This master thesis, and the research project of 
which it is part, may contribute to an increased knowledge of what factors are of prognostic 
relevance concerning PCI in the elderly with ACS. Such increased knowledge could in turn 
facilitate clinical decision-making to the benefit of patients. 
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METHODS 
STUDY POPULATION  
The study population of this master thesis is composed of patients ≥ 80 years who underwent 
PCI at the Sahlgrenska University Hospital in Gothenburg, Sweden, during 2006-2007. The 
time-period 2006-2007 was chosen to allow for a follow-up period of 4-5 years. Performed 
PCI procedures for the specified age group and time period were identified from medical 
records. Within the framework of this study 125 out of the identified procedures were 
assessed. A number of exclusion criteria were applied to identify the procedures that were to 
be included in the study. Firstly, since the catchment area of the Sahlgrenska University 
Hospital for performing PCI during emergency hours is larger than during office hours a 
substantial amount of the procedures were performed in individuals who are not normally 
patients of the hospital. These procedures (n=33) were excluded from the study since medical 
records from before and after the procedure were not accessible for these patients. Secondly, 
in some cases (n=16) two or more PCI procedures were performed in the same patient. In 
these cases only the first PCI the individual patient underwent after the age of ≥ 80 years were 
included. Thirdly, since the objective of the study is to evaluate prognosis after PCI in ACS, 
elective PCI procedures with the indication of stable angina pectoris (n=9) were excluded. 
Finally, a few procedures (n=3) involved only coronary angiography without balloon 
dilatation and stent implantation. These procedures, incorrectly labeled as PCI, were also 
excluded. After excluding PCI procedures according to the criteria described above 64 
procedures in 64 individual patients remained. These procedures and patients constitute the 
study population of this thesis.          
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DATA COLLECTION  
A thorough survey of the medical records of each individual patient was conducted. Medical 
records at the Sahlgrenska University Hospital are electronically stored since the middle of 
the 1990s.  All electronically stored information, from all clinical departments of the hospital, 
concerning the time period before the PCI and up until 4-5 years1 after the procedure was 
surveyed. Data on a total number of about 170 variables and 6 outcome measures were, when 
available, registered in a database. The registered variables could be summarized in 12 
principal categories: basic demographics (age, sex), social conditions (e.g. marital status and 
level of education), functional status (e.g. level of physical exercise and independence in 
ADL), basic clinical parameters (e.g. BMI, blood pressure at admission and discharge), 
changes in the ECG, PCI-related variables (e.g. type and number of stents used), UCG-related 
variables, prior cardiovascular interventions, cardiovascular risk factors and diseases, other 
co-morbidities (somatic and psychiatric), laboratory parameters (admission and discharge) 
and medications (admission and discharge). Registered outcome measures included mortality, 
cardiovascular events and symptoms, hospital readmissions and functional status (level of 
independence in ADL and physical capabilities). 
ETHICAL CONSIDERATIONS 
This master thesis, and the research project it is part of, involved the collection of sensitive 
personal data concerning the health status of living persons. In accordance with the Personal 
Data Act (1998:204) and the Act Concerning the Ethical Review of Research Involving 
Humans (2003:460) a permission from the Regional Ethical Review Board, Gothenburg, was 
obtained before data collection was initiated.  
 
                                                 
1 For patients undergoing PCI during April-December 2007 the retrospective follow-up period was between 4 
and 5 years. Patients undergoing PCI in 2006 and between January-March 2007 were retrospectively followed-
up for 5 years. 
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STATISTICAL METHODS 
Statistical analysis was, due to the limited scope of this master thesis, performed on a 
selection of 48 of the variables on which data was completed. Variables assumed to be 
independent of each other and of particular prognostic significance were selected2. Moreover, 
variables for which sufficient data was available were selected. All-cause mortality at 4 years 
was used as the outcome measure of the analyses. All statistical analyses were made using 
SPSS® software (version 20, SPSS Inc., Chicago, IL, USA). A p-value of <0.05 was 
considered significant. 
   Patients were divided into two groups: those who died during the follow-up period and 
those who were still alive 4 years after undergoing PCI. Baseline characteristics of the two 
patient groups are presented as percentages for categorical (or discrete) variables and as 
means and standard deviations for numerical (or continuous) variables. Values for troponin T 
and I, which are not normally distributed variables, are presented as medians and quartiles. P-
values were calculated in order to determine if there were any significant differences between 
the patient groups (‘dead’ and ‘alive’) at baseline. The Pearson’s chi-square test was used to 
calculate p-values for categorical variables. For normally distributed numerical variables the 
t-test was used while for troponin T and I the Mann-Whitney test was used. Normality of the 
distribution of the variables was tested by means of histograms. 
   Univariate regression analysis was performed to determine whether there was any 
statistically significant relation between each single variable and mortality over time. For 
troponin T and I logarithmic values were used to adjust for their abnormal distribution. 
Results of the univariate analysis are presented as hazard ratios (HR). Confidential intervals 
of 95% were calculated for HRs. 
                                                 
2 Selected variables are listed in table 1. 
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   In order to determine which variables that were independently related to mortality 
multivariate Cox regression analysis was performed on variables which were found to be of 
significance in the univariate analysis. Multivariate regression analysis including all 
significant variables was conducted. However, since the study population and number of 
events (i.e. deaths) was relatively small, multivariate analyses were also conducted on a 
smaller number of covariates at a time. In this way, the applicability of the results to the 
general population was increased. 
   Survival analysis was performed to illustrate how different variables were related to 
survival over time. Kaplan-Meier curves, showing the fraction of patients being alive at 
different points of time after PCI, were constructed for all variables found to be significantly 
connected to mortality in the univariate regression analysis. For numerical variables patients 
were grouped into categories using clinically relevant limit values. The Logrank test was used 
to establish whether there were any significant differences between patient groups with regard 
to survival curves.  
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RESULTS 
BASELINE CHARACTERISTICS 
Baseline demographic and clinical characteristics of the total study cohort as well as of the 
two patient groups ‘dead’ and ‘alive’ are presented in Table 1. 26 patients, about 40%, out of 
the total number of 64 patients died during follow-up. The mean age of the total study cohort 
was 83.9±3.2 years. The patients who died during follow-up were slightly older than the 
patients who were still alive 4 years after the PCI procedure. However, the difference in mean 
age was not significant. Additionally, with 65.4% of the patients who died and 60.5% of the 
patients who were still alive at 4 years being male, there was no significant difference in the 
proportion of men between the two patient groups. 
   Patients who died were living alone to a greater extent than those who survived follow-up. 
Moreover, they were more dependent in ADL. However, the differences in social conditions 
and functional status between the patient groups at admission were not significant.  
   With the exception of glomerular filtration rate (GFR) and congestive heart failure there 
were no significant differences between the two patient groups concerning basic clinical 
parameters, laboratory parameters, cardiovascular risk factors and diseases, interventions, co-
morbidities and medication (Table 1). Patients who died during follow-up had significantly 
lower mean GFR at admission than patients being alive at 4 years follow-up (46.4±16.4 
compared to 59.0±17.3 ml/min, p<0.01). When GFR at admission was further divided into 
categories of <60 and <30 ml/min both were significantly more frequent in patients who died. 
The proportion of patients with a history of symptomatic congestive heart failure was 23.1% 
among patients who died during follow-up compared to 5.3% among patients who still lived 
at 4 years after the PCI. A left-ventricular ejection fraction (LVEF) of less than 40% was 
more common among patients who died during follow-up, but not significantly so.    
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FOLLOW-UP 
Results of the univariate and multivariate regression analyses are presented in Table 2 and 3 
respectively. 6 of the 48 variables were found to be significantly related to mortality over time 
in the univariate regression analysis; age, heart rate, haemoglobin levels, glomerular filtration 
rate, congestive heart failure and prior CABG. Furthermore, as already mentioned, 
multivariate regression analysis was performed in different multivariate models. Firstly, all 
significant variables (Table 2) were included. Secondly, considering the limited number of 
events, only 3 significant variables were included in 4 different multivariate models (Table 3). 
When all significant variables from the univariate regression analysis were entered into 
multivariate analysis 2 of the 6 variables, heart rate and prior CABG, were revealed to be 
independently predictive of mortality over time. As seen in Table 2, heart rate had a HR of 
1.022 (95% CI 1.01-1.04, p<0.05) and prior CABG a HR of 4.278 (95% CI 1.04-17.68, 
p<0.05) in this analysis. Results of the additional 4 multivariate models, including only 3 
significant variables, are presented in Table 3. As seen in this table heart rate remained an 
independent predictor of mortality in all of these models while prior CABG was significantly 
related to mortality in only two of the models. Age and GFR were, in contrast to the results of 
the multivariate regression analysis including all significant variables from the univariate 
analysis, also found to be significantly related to mortality. However, haemoglobin levels and 
congestive heart failure were not. 
    
Kaplan-Meier survival curves are shown in Figure 1-6. Figure 1 illustrates that cumulative 
survival was significantly lower for patients with an age of ≥85 years compared to patients 
with an age of 80-84 years. Concerning heart rate a trend towards lower survival rates with 
increasing heart rate is illustrated in Figure 2.A-D. However, a significant difference in 
survival between patient groups was only seen when a heart rate of > 100 beats/min was used 
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as limit value (Figure 2-D). However, as seen in Figure 2-D, only 3 out of the patients who 
died during follow-up had a heart rate of > 100 beats/min at admission. All of these patients 
died during the first year after the PCI procedure. Survival rates according to haemoglobin 
levels are shown in Figure 3. A haemoglobin level of < 120 g/L, which is the WHO definition 
of anemia for men, did not entail significantly lower survival rates (Figure 3-A). Severe 
anemia, defined as haemoglobin levels of < 110 g/L, was however related to significantly 
lower survival (Figure 3-B). In regard to glomerular filtration rate Kaplan-Meier survival 
curves were constructed with limit values of 60 ml/min, equivalent to a moderate reduction of 
renal function, and 30 ml/min, equivalent to a severe reduction of renal function (Figure 4.A-
B). Survival rates were, as seen in Figure 4.A, significantly lower even for a moderately 
reduced renal function. Kaplan-Meier survival curves for the categorical variables congestive 
heart failure and prior CABG are presented in Figure 5 and 6 respectively. Concerning prior 
CABG curves cross at about 4 months after the PCI indicating that the HR for this variable 
was not proportional over time. 
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DISCUSSION 
The primary findings of this study were that age, heart rate, glomerular filtration rate and 
prior CABG were independent predictors of all-cause mortality among those aged ≥ 80 years 
having undergone PCI at 4 years follow-up.  
   This retrospective study was conducted in a study population of 64 patients ≥ 80 years with 
ACS undergoing PCI during 2006-2007. As shown in Table 1, this was a highly selected 
patient group. Indications of selection include well-controlled blood pressure, a majority in 
sinus rhythm and proportions of only 15% with a reduced LVEF and 13% with symptomatic 
heart failure. This reflects the reality of daily clinical practice in the elderly patient population 
where evidence is lacking and decision-making is often empiric. However, despite this 
selection, and allowing for this pilot study of predictive modeling among elderly patients 
undergoing PCI, 4 year all-cause mortality was still more than 40%.  
   Among the variables found to be independent predictors of 4 year all-cause mortality in the 
current study age, with a HR of 1.167, was one of the strongest. This variable has previously 
been demonstrated to be an independent predictor of mortality after PCI among patients ≥ 80 
years (15, 16, 18, 20, 25). However, there are also studies with conflicting results concerning 
the prognostic effect of age (21, 27, 31). For example, Kamiya et al. (27) found that among 
patients ≥ 80 years an age of ≥ 85 years was not predictive of 5-year mortality. This might be 
due to differences in sample size and study design. Similar inconsistency, indicating that 
findings from patients ≥ 80 years are not necessarily comparable to those from patients >85 
years, has been found concerning the prognostic effects of renal insufficiency on mortality 
(27, 31). In accordance with previous results (3), heart rate was shown to be a predictor of 
long-term mortality in this study. Moreover, renal insufficiency and prior CABG were 
demonstrated to be of negative prognostic significance in the current study population. 
 15 
 
Concerning renal insufficiency it has been shown to constantly worsen prognosis in a 
continuum of cardiovascular disease. Prior CABG was found to be an independent predictor 
of mortality possibly because it indicates advanced coronary artery disease.  
 
The finding of this study that age is one among several factors of prognostic significance 
concerning patients ≥ 80 years undergoing PCI supports the hypothesis that there is a 
subgroup of elderly patients with better prospects of gaining from intervention than others. 
This thesis may have added to prior knowledge on which variables that are of relevance in the 
identification of this patient subgroup. The current study clearly indicates that a high heart 
rate, reduced glomerular filtration rate and prior CABG are of negative prognostic 
significance implying that patients with the above-mentioned factors probably have less to 
gain from PCI in the setting of ACS. Still, these results need to be validated in a prospective 
manner and further studies are needed to test the hypothesis. This study mainly focused on the 
prognostic significance of clinical characteristics such as laboratory parameters, 
cardiovascular risk factors, co-morbidities and medications. Even if clinical characteristics 
have been shown to be more prognostically important among patients ≥ 80 years (18) the 
evaluation of variables related to e.g. the PCI procedure would be valuable. As described in 
the methods section, data on 170 variables, including additional clinical as well as PCI-related 
ones, and 6 outcome measures were collected for this master thesis creating opportunities for 
further analyses. A more comprehensive retrospective study is performed within the 
framework of the larger research project of which this thesis constitutes part. This extended 
study, which also comprises a larger study population (n=200), among other things aims at 
evaluating predictors of long-term symptom relief and functional outcome. These outcome 
measures, which in turn are related to quality of life, are of great interest concerning elderly 
patients for whom the remaining expected length of life may be limited. Furthermore, within 
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the framework of an extended retrospective study, it would be interesting to evaluate 
predictors of long-term outcome for the different PCI indications (UAP, NSTEMI and 
STEMI) separately. Patients presenting with NSTE-ACS constitute a more heterogeneous 
population in terms of risks and prognosis than patients presenting with STEMI(7). A separate 
analysis of elderly patients presenting with NSTE-ACS would, as decision-making in this 
patient group may be particularly complicated, therefore be interesting. Apart from extended 
retrospective analysis further prospective randomised studies are also needed to allow for the 
identification of the subgroup of elderly patients who have prospects of benefiting from PCI. 
A prospective study of patients ≥ 80 years undergoing PCI in the setting of ACS is currently 
conducted at the Sahlgrenska University Hospital. This study includes a control group of 
patients who are randomised to either PCI or conservative treatment and will, together with 
the retrospective analysis described above, form the basis for the elaboration of a predictive 
model that can be used in clinical decision-making. 
 
STUDY LIMITATIONS 
One of the main limitations of this study is its retrospective design. For some of the variables 
and outcome measures data were scarce. Another main limitation is the lack of a control 
group, e.g. patients ≥ 80 years who underwent other treatment than PCI. The fact that the 
study is not randomized and only includes patients undergoing PCI poses a risk of a selection 
bias. As discussed above, it is likely that the elderly patients who have been considered as 
suitable candidates for PCI are healthier than the general population of patients ≥ 80 years 
with ACS. Furthermore, an important limitation of this study is that the study population is 
relatively small. In particular, the number of events (i.e. deaths) in relation to the variables 
included in the multivariate regression analysis is limited, calling for caution when 
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interpreting the results. Finally, this was a single-center study and so the possibilities for 
extrapolation of results to other centers are limited. 
 
CONCLUSIONS 
In summary, this study showed that age, heart rate, glomerular filtration rate and prior CABG 
were independent predictors of all-cause mortality among patients aged ≥ 80 years undergone 
PCI upon 4 years follow-up. In order to establish with greater certainty what factors other 
than age that are of prognostic significance, and their relative importance, further studies are 
however required. Such studies would facilitate decision-making on the use of PCI in a 
patient group that, in view of the aging of populations, constitutes an increasing part of the 
general patient population. This in turn would, both by decreasing the risk of use in patients 
for whom risks exceed benefits and increasing the probability of use in patients for whom 
benefits exceed risks, lead to a more optimal use of PCI and so in the end gain patients 
 
 
 
 
 
 
 
 
 
 
 
  
 18 
 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Hjärt-kärlsjukdomar är den kategori av sjukdomar som orsakar mest sjuklighet och flest 
dödsfall i världen. Den vanligaste typen av hjärt-kärlsjukdom är kranskärlssjukdom, det vill 
säga sjukdom i de artärer som försörjer hjärtat med blod. Kranskärlssjukdom orsakas av en 
process som kallas för ateroskleros och som innebär att blodfetter lagras in i kärlväggen och 
bildar så kallade plack. Utvecklingen av plack sker långsamt och påverkas av ett antal 
riskfaktorer som till exempel rökning, högt blodtryck och höga blodfetter. 
   Kärl där plack har bildats blir trängre och blodflödet i kärlet försämras därmed. När detta 
sker i hjärtats kranskärl kan syrebrist uppstå i hjärtmuskeln. Det vanligaste symtomet på 
syrebrist i hjärtmuskeln är kärlkramp, det vill säga bröstsmärta som framför allt kommer vid 
fysisk ansträngning då syrebehovet i hjärtmuskeln ökar. Kranskärlssjukdom kan också orsaka 
hjärtinfarkt. Det som händer vid hjärtinfarkt är att ett plack plötsligt går sönder så att kroppens 
koagulationssystem aktiveras och en blodpropp bildas. Blodproppen täpper i sin tur helt eller 
delvis till kärlet. Syrebristen i den del av hjärtmuskeln som försörjs av det kärl som täppts 
igen blir då så stor att hjärtmuskelceller dör. En hjärtinfarkt ger ofta kraftigare bröstsmärta än 
kärlkramp och diagnostiseras med hjälp av EKG och blodprov som mäter ett protein, 
troponin, som läcker ut i blodet från skadade hjärtmuskelceller. 
   Ett av de viktigaste målen med behandling av kranskärlssjukdom är att förhindra att 
aterosklerosen, eller åderförfettningen, förvärras och därmed minska risken för hjärtinfarkt. 
Detta gör man bland annat med hjälp av livsstilsförändringar som ökad fysisk aktivitet och 
rökstopp och med hjälp av läkemedel mot högt blodtryck och höga blodfetter. När en 
hjärtinfarkt väl utvecklats är det viktigt att, för att minska risken för att hjärtmuskelceller dör 
och begränsa skadan på hjärtmuskeln, öppna upp det kärl som täppts till. På så sätt minskar 
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risken för att hjärtsvikt, det vill säga en minskad förmåga för hjärtat att pumpa ut blod, och 
rytmrubbningar utvecklas som komplikation till hjärtinfarkten.  
   En propp som bildats i ett kranskärl kan lösas upp med läkemedel. I de flesta fall föredrar 
man dock att behandla en akut hjärtinfarkt med ballongvidgning, eller perkutan koronar 
intervention (PCI). Denna behandling ska ges så fort som möjligt efter att diagnosen 
hjärtinfarkt ställts. En ballongvidgning inleds med att man går in med en smal slang, eller 
kateter, i ett kärl i handleden eller ljumsken och, via kroppspulsådern, till hjärtats kranskärl. 
Via denna kateter sprutas kontrastmedel in samtidigt som röntgenbilder tas. Genom att titta på 
hur kontrastmedlet sprids i hjärtats kranskärl kan man identifiera det kärl som är tilltäppt. 
Detta kärl kan sedan öppnas upp med hjälp av en ballong som förs in genom samma kateter 
som använts för att spruta in kontrastmedel och som blåses upp vid det ställe där kärlet är 
tilltäppt. Efter att ballongen blåsts upp läggs vanligtvis ett litet metallnät, eller stent, in för att 
förhindra nya förträngningar. 
 
Nyttan med ballongvidgning vid hjärtinfarkt är välstuderad. När det gäller äldre människor är 
dock kunskapen om behandlingen, trots att äldre utgör den största delen av patienter med 
hjärtinfarkt, fortfarande begränsad. Studier har visat att äldre patienter generellt har större risk 
att drabbas av komplikationer och att avlida i samband med ballongvidgning än yngre 
patienter. Hög ålder i sig verkar vara en faktor som påverkar prognosen vid ballongvidgning 
negativt. Äldre utgör dock en brokig grupp när det gäller bland annat samsjuklighet och 
vitalitet. Sannolikt är det därmed också så att det bland äldre personer finns en stor variation 
både i risken av att drabbas av komplikationer av ballongvidgning och chansen att dra nytta 
av behandlingen. Problemet idag är att man inte med tillräcklig stor säkerhet vet vilka andra 
faktorer än den höga åldern som påverkar prognosen. Detta gör det svårt för läkare att fatta 
välgrundade beslut om behandling av äldre personer med hjärtinfarkt. I sin tur leder detta till 
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en risk för att äldre patienter som skulle dra nytta av ballongvidgning undanhålls behandling, 
och tvärtom, att patienter där riskerna med ballongvidgning egentligen kan anses vara för 
stora i förhållande till de möjliga vinsterna ändå genomgår behandling.  
   Syftet med detta examensarbete har varit att studera och identifiera faktorer som påverkar 
prognosen efter ballongvidgning hos äldre personer med hjärtinfarkt. Arbetet ingår i ett större 
forskningsprojekt som har som slutgiltigt mål att, utifrån en ökad kunskap om prognostiska 
faktorer, utarbeta en modell som läkare ska kunna använda som beslutsstöd när det gäller 
ballongvidgning hos äldre patienter. Som underlag för examensarbetet har information som 
samlats in från journaler för 64 patienter ≥80 år som genomgått ballongvidgning på 
Sahlgrenska Universitetssjukhuset i Göteborg under 2006-2007 använts. Från journalerna har 
bland annat information om vilka sjukdomar förutom hjärtinfarkt patienterna hade, vilka 
läkemedel de använde, hur fysiskt aktiva de var och vad blodprover i samband med 
ballongvidgningen visade inhämtats. Journalerna har också gåtts igenom för att se hur det gått 
för patienterna till och med 4-5 år efter ballongvidgningen. Det visade sig att cirka 40 % av 
patienterna avlidit under uppföljningsperioden på 4-5 år. Med hjälp av statistiska analyser 
kunde det konstateras att en ålder över 85 år, en hjärtfrekvens på mer än 100 slag i minuten 
vid ankomsten till sjukhuset, nedsatt njurfunktion och att tidigare ha genomgått en bypass-
operation på hjärtats kranskärl var faktorer som påverkade prognosen efter ballongvidgningen 
negativt. Av detta kan man dra slutsatsen att, i gruppen 80 år eller äldre, är patienter med de 
faktorer som beskrivits ovan troligen mindre lämpliga att genomgå ballongvidgning. 
   Resultaten från den här studien behöver kompletteras med ytterligare studier. Med hjälp av 
fler studier skulle läkare med större säkerhet kunna avgöra vilka äldre patienter som bör 
genomgå ballongvidgning vid hjärtinfarkt. Genom att minska risken för både över- och 
underbehandling skulle detta i slutändan främja patienterna.  
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APPENDIX: TABLES AND FIGURES 
 
Table 2. Univariate and multivariate regression analyses of 4-year all-cause mortality in total 
study cohort 
 Univariate Multivariate 
Total study cohort HR 95% CI P-value HR 95% CI P-value 
Age 1.135 1.02-1.27 0.025* 1.074 0.92-1.25 0.369 
Heart rate 1.016 1.00-1.03 0.018* 1.022 1.01-1.04 0.014* 
Haemoglobin levels 0.973 0.95-1.00 0.026* 0.991 0.96-1.02 0.532 
Glomerular filtration rate 0.963 0.94-0.99 0.007** 0.973 0.94-1.00 0.074 
Congestive heart failure 3.043 1.21-7.63 0.018* 1.200 0.28-5.20 0.807 
Prior CABG 3.281 1.11-9.67 0.031* 4.278 
1.04-
17.68 0.045* 
 
 
Table 3. Different models for multivariate regression 
analysis of 4-year all-cause mortality in total study 
cohort 
Model 1 HR 95% CI P-value 
Age 1.167 1.03-1.33 0.019* 
Heart rate 1.019 1.00-1.04 0.017* 
Prior CABG 4.772 1.46-15.60 0.010* 
Model 2  
Haemoglobin levels 0.990 0.96-1.02 0.491 
Heart rate 1.016 1.00-1.03 0.040* 
Prior CABG 2.753 0.84-9.02 0.094 
Model 3  
Glomerular filtration 
rate 0.965 0.94-0.99 0.011* 
Heart rate 1.024 1.01-1.04 0.008** 
Prior CABG 4.204 1.33-13.25 0.014* 
Model 4  
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   Congestive heart 
failure 2.796 0.94-8.40 0.066 
Heart rate 1.016 1.00-1.03 0.031* 
Prior CABG 2.147 0.65-7.11 0.211 
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Table 1. Baseline demographic and clinical characteristics of patients 
 Total study cohort Dead Alive 
    
   Age (years) (mean±SD)    
   Male (%) 
n=64 
83.9±3.2 
62.5 
n=26 
84.8±3.7 
65.4 
n=38 
83.2±2.7 
60.5 
Social Conditions and Functional Status 
   Living alone (%) 
   Dependent in ADL (%) 
 
35.5 
3.1 
 
41.7 
7.7 
 
31.6 
0.0 
Basic Clinical Parameters1   
   BMI (kg/m2) (mean±SD) 
   Systolic BP (mmHg) (mean±SD) 
   Diastolic BP (mmHg) (mean±SD) 
   Heart rate (beats/min) (mean±SD) 
   Sinus rhythm (%) 
   LVEF <40% (%) 
   Time onset of symptoms-PCI (hours) (mean±SD) 
   PCI indication 
      Unstable angina pectoris (%) 
      NSTEMI (%) 
      STEMI (%) 
 
25.4±3.9 
150.7±26.8 
83.0±15.2 
79.0±25.2 
86.2 
14.8 
111.1±153.2 
 
12.5 
35.9 
51.6 
 
25.5±4.7 
148.8±27.3 
81.0±12.0 
85.6±35.5 
79.2 
17.4 
112.0±135.1 
 
7.7 
42.3 
50.0 
 
25.2±3.4 
152.1±26.8 
84.4±17.3 
74.5±13.0 
91.2 
12.9 
110.4±167.7 
 
15.8 
31.6 
52.6 
Laboratory Parameters2 
   Haemoglobin (g/L)(mean±SD) 
   Sodium (mmol/L) (mean±SD) 
   Potassium (mmol/L) (mean±SD) 
   GFR (ml/min) (mean±SD)3 
   Leukocyte count (x109/L) (mean±SD) 
   PT(INR) (mean±SD) 
   Total cholesterol (mmol/L) (mean±SD)  
   Troponin T (µg/L) (median(25th-75th percentile)) 
   Troponin I (µg/L) (median(25th-75th percentile)) 
 
133.3±17.3 
138.7±3.1 
4.1±0,5 
53.9±17.9 
9.3±2.9 
1.3±0.5 
4.5±1.1 
1.01(0.25-4.66) 
4.0(1.3-7.0) 
 
128.2±17.0 
138.4±3.4 
4.1±0.6 
46.4±16.4** 
9.6±3.7 
1.3±0.6 
4.6±1.2 
1.79(0.25-4.72) 
1.67(0.10-1.67) 
 
136.8±16.8 
138.9±3.0 
4.0±0.4 
59.0±17.3 
9.1±2.1 
1.2±0.4 
4.4±1.0 
0.98(0.25-4.57) 
4.0(1.42-10.00) 
Cardiovascular Risk Factors 
   Current smoker (%) 
   Ever smoker (%)4 
   Hypertension (%) 
   Diabetes mellitus (%) 
   Hypercholesterolemia (%) 
 
6.7 
71.7 
65.6 
23.4 
30.2 
 
8.0 
81.3 
73.1 
34.6 
34.6 
 
5.7 
66.7 
60.5 
15.8 
27.0 
Cardiovascular Diseases  
   Prior MI (%) 
   Angina pectoris (%) 
   Atrial fibrillation (%) 
   Congestive heart failure (%) 
   Peripheral arterial disease (%) 
 
29.7 
45.3 
20.3 
12.5 
9.4 
 
42.3 
50.0 
23.1 
23.1* 
11.5 
 
21.1 
42.1 
18.4 
5.3 
7.9 
Interventions 
   Prior CABG (%) 
   Prior PCI (%) 
 
7.8 
10.9 
 
15.4 
11.5 
 
2.6 
10.5 
Co-morbidities 
   Stroke/TIA (%) 
   Pulmonary disease (%) 
   Psychiatric disorder (%) 
   GFR <60 ml/min (%)  
   GFR<30 ml/min (%) 
 
17.2 
18.8 
15.6 
64.5 
6.5 
 
15.4 
23.1 
19.2 
80.0* 
16.0* 
 
18.4 
15.8 
13.2 
54.1 
0.0 
Medication5 
   Aspirin (%) 
   Clopidogrel (%) 
   Warfarin (%) 
   Beta-blocker (%) 
   ACEi/Angiotensin receptor II blocker (%) 
   Calcium antagonist (%) 
   Diuretics (%) 
   Digoxin (%) 
 
54.8 
9.8 
6.3 
56.5 
31.1 
32.8 
32.8 
9.7 
 
69.2 
8.0 
7.7 
61.5 
44.0 
40.0 
42.3 
8.3 
 
44.4 
11.1 
5.4 
52.8 
22.2 
27.8 
25.0 
10.5 
1BMI, systolic BP, diastolic BP, heart rate and sinus rhythm: values at admission. LVEF >40%: during hospitalization. 
2Troponin T and I: maximum value during hospitalization. All other laboratory parameters: value at admission. 3GFR 
according to Cockcroft-Gault. 4Current or former smoker. 5Digoxin at admission or during hospitalization. All other 
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Figure 1. Long-term survival according to age 
 
 
 
 
 
Figure 2. Long-term survival according to heart rate 
 
 
medications at admission only. *p<0.05 dead compared with alive, **p<0.01 dead compared with alive 
A B 
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Figure 3. Long-term survival according to haemoglobin levels 
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Figure 4. Long-term survival according to glomerular filtration rate 
 
 
  
 
 
 
 
Figure 5. Figure 6. 
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